{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated|Treatment of pancreatic cancer" in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT02945267: Phase 4 Interventional Unknown status Unresectable Pancreatic Cancer
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01028495: Phase 2 Interventional Completed Metastatic Pancreatic Cancer
(2009)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00761280: Phase 3 Interventional Terminated Anaplastic Astrocytoma
(2008)
Source URL:
Class:
NUCLEIC ACID
Status:
First approved in 1963
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04215146: Phase 2 Interventional Active, not recruiting Breast Cancer Metastatic
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04442048: Phase 3 Interventional Active, not recruiting Cancer
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00040092: Phase 3 Interventional Completed Pancreatic Cancer
(2002)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Designated
Source:
FDA ORPHAN DRUG:877922
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03573544: Phase 1/Phase 2 Interventional Terminated Metastatic Solid Tumors
(2018)
Source URL:
Class:
CONCEPT
Status:
Designated
Source:
FDA ORPHAN DRUG:814521
Source URL:
Class:
CONCEPT
